• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships

    5/30/25 11:01:18 AM ET
    $MSFT
    $TVGN
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MSFT alert in real time by email

    WARREN, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today provided stockholders with a detailed overview of its artificial intelligence initiative, Tevogen.AI™.

    Tevogen.AI™ aims to integrate advanced machine learning and predictive modeling into Tevogen Bio's proprietary ExacTcell™ technology to significantly enhance its target identification and pre-clinical processes, thereby strengthening the Company's pipeline of innovative immunotherapies, accelerating clinical timelines, and substantially reducing development costs.

    Tevogen.AI currently has two proprietary technologies, each with patents pending, and an internal valuation of these assets is forthcoming. The Company plans to expand its AI initiative with applications that extend well beyond Tevogen Bio. In preparation for this anticipated growth, Tevogen is expanding its headquarters to include dedicated facilities for Tevogen.AI's team of data scientists and engineers.

    Tevogen CEO, Dr. Ryan Saadi, commented, "Healthcare is one of the largest segments of our economy, projected to approach $5 trillion in the U.S. in 2025 and a significant contributor to our rising national debt. Tevogen.AI's vision extends beyond transforming how therapies are developed; it is expected to make a meaningful impact across multiple sectors of healthcare. I applaud the leadership team at Tevogen.AI and our strategic partners for their innovative efforts and contributions that will help define the future of healthcare."

    Strategic Partnerships:

    Microsoft (NASDAQ:MSFT): Provides industry-leading AI expertise, cloud computing infrastructure (Azure), and scientific resources to accelerate drug discovery processes.

    Databricks: Supplies specialized data engineering and analytics capabilities to refine Tevogen's AI models and enhance predictive accuracy.

    Proprietary Tevogen.AI Technology:

    PredicTcell™: AI tools capable of accurately predicting immunologically active peptide complexes and their interactions with T cell receptors, driving precision in immunotherapy treatments.

    The PredicTcell platform is a collection of multiple algorithms which performs in-silico predictions for candidate selection across multiple diseases. It continually improves with each accurate prediction through model tuning and reinforcement, helping expand our understanding of T cell receptor bindings, and therefore shortening the in-vivo process and expanding Tevogen Bio's pipeline. To date, Tevogen.AI has developed a continually expanding, terabyte-scale database that processes millions of protein and peptide interactions spanning numerous diseases and the human genome.

    AdapTcell™: Algorithms to decode the interactions between human leukocyte antigens (HLA) and T cells.

    AdapTcell is expected to significantly enhance Tevogen Bio's understanding of immune responses and open new therapeutic avenues, especially in areas with minimal existing data. As our understanding of key interactions expand, AdapTcell built algorithms perform experiments unlocking insights into genetics and proteomics. The platform aims to expand upon the cross sections of genetics and protein interactions and build an HLA specificity map.

    Tevogen.AI plans to expand into clinical trial patient identification using the information collected from its PredicTcell and AdapTcell platforms to drive efficiency, cost reduction and deliver targeted results.

    Tevogen remains committed to transparent communication with its stockholders and will continue providing clear updates on the progress and achievements of Tevogen.AI.

    Forward Looking Statements

    This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen's plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as "may," "could," "would," "expect," "anticipate," "possible," "potential," "goal," "opportunity," "project," "believe," "future," and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.

    Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's Annual Report on Form 10-K.

    You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.

    Contacts

    Tevogen Bio Communications

    T: 1 877 TEVOGEN, Ext 701

    [email protected]



    Primary Logo

    Get the next $MSFT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MSFT
    $TVGN

    CompanyDatePrice TargetRatingAnalyst
    Microsoft Corporation
    $MSFT
    5/1/2025$430.00 → $494.00Overweight
    Barclays
    Microsoft Corporation
    $MSFT
    5/1/2025$475.00 → $500.00Buy
    Stifel
    Microsoft Corporation
    $MSFT
    5/1/2025$480.00 → $490.00Outperform
    Raymond James
    Microsoft Corporation
    $MSFT
    5/1/2025$500.00 → $525.00Outperform
    RBC Capital Mkts
    Microsoft Corporation
    $MSFT
    5/1/2025$435.00 → $475.00Overweight
    Piper Sandler
    Microsoft Corporation
    $MSFT
    5/1/2025$475.00 → $515.00Outperform
    Wedbush
    Microsoft Corporation
    $MSFT
    5/1/2025$475.00 → $500.00Outperform
    Mizuho
    Microsoft Corporation
    $MSFT
    5/1/2025$450.00 → $480.00Buy
    Goldman
    More analyst ratings

    $MSFT
    $TVGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Barclays reiterated coverage on Microsoft with a new price target

      Barclays reiterated coverage of Microsoft with a rating of Overweight and set a new price target of $494.00 from $430.00 previously

      5/1/25 7:50:05 AM ET
      $MSFT
      Computer Software: Prepackaged Software
      Technology
    • Stifel reiterated coverage on Microsoft with a new price target

      Stifel reiterated coverage of Microsoft with a rating of Buy and set a new price target of $500.00 from $475.00 previously

      5/1/25 7:49:44 AM ET
      $MSFT
      Computer Software: Prepackaged Software
      Technology
    • Raymond James reiterated coverage on Microsoft with a new price target

      Raymond James reiterated coverage of Microsoft with a rating of Outperform and set a new price target of $490.00 from $480.00 previously

      5/1/25 7:49:44 AM ET
      $MSFT
      Computer Software: Prepackaged Software
      Technology

    $MSFT
    $TVGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $MSFT
    $TVGN
    Financials

    Live finance-specific insights

    See more
    • Chief Financial Officer Desai Kirti bought $2,460 worth of shares (3,000 units at $0.82), increasing direct ownership by 0.03% to 9,699,186 units (SEC Form 4)

      4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

      6/13/24 4:30:24 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Saadi Ryan H. bought $2,000 worth of shares (2,607 units at $0.77), increasing direct ownership by 0.00% to 118,252,659 units (SEC Form 4)

      4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

      6/7/24 4:29:51 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Microsoft earnings press release available on Investor Relations website

      REDMOND, Wash., April 30, 2025 /PRNewswire/ -- Microsoft Corp. on Wednesday announced that fiscal year 2025 third-quarter financial results are available on its Investor Relations website. The direct link to the earnings press release is https://www.microsoft.com/en-us/Investor/earnings/FY-2025-Q3/press-release-webcast. As previously announced, the company will host a conference call at 2:30 p.m. Pacific Time. A live webcast of the call can be accessed on Microsoft's Investor Relations website at https://www.microsoft.com/en-us/Investor/. Microsoft (Nasdaq "MSFT" @microsoft) c

      4/30/25 4:04:00 PM ET
      $MSFT
      Computer Software: Prepackaged Software
      Technology
    • Microsoft announces quarterly earnings release date

      REDMOND, Wash., April 9, 2025 /PRNewswire/ -- Microsoft Corp. will publish fiscal year 2025 third-quarter financial results after the close of the market on Wednesday, April 30, 2025, on the Microsoft Investor Relations website at https://www.microsoft.com/en-us/Investor/. A live webcast of the earnings conference call will be made available at 2:30 p.m. Pacific Time. Microsoft (Nasdaq "MSFT" @microsoft) creates platforms and tools powered by AI to deliver innovative solutions that meet the evolving needs of our customers. The technology company is committed to making AI avail

      4/9/25 4:07:00 PM ET
      $MSFT
      Computer Software: Prepackaged Software
      Technology
    • Microsoft announces quarterly dividend

      REDMOND, Wash., March 11, 2025 /PRNewswire/ -- Microsoft Corp. on Tuesday announced that its board of directors declared a quarterly dividend of $0.83 per share. The dividend is payable June 12, 2025, to shareholders of record on May 15, 2025. The ex-dividend date will be May 15, 2025. Microsoft (Nasdaq "MSFT" @microsoft) creates platforms and tools powered by AI to deliver innovative solutions that meet the evolving needs of our customers. The technology company is committed to making AI available broadly and doing so responsibly, with a mission to empower every person and ev

      3/11/25 4:04:00 PM ET
      $MSFT
      Computer Software: Prepackaged Software
      Technology

    $MSFT
    $TVGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

      WARREN, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today reminds that CEO Dr. Ryan Saadi MD, MPH will participate in BioNJ's Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at Morgan Lewis. Along with Dr. Ryan Saadi, the panel will also include commentary from Matt Vamvakis, MBA, Managing Director, J.P. Morgan Private Bank, Amanda Laskey, Life Sciences Senior Analyst, RSM US, and Kee Colon, MBA, Managing Director, Cantor Fitzgerald. The conference, held on May 13, 2025,

      4/29/25 8:00:00 AM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

      WARREN, N.J., April 14, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announces CEO Dr. Ryan Saadi, MD, MPH, will participate in BioNJ's Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at Morgan Lewis. Along with Dr. Ryan Saadi, the panel will also include commentary from Matt Vamvakis, MBA, Managing Director, J.P. Morgan Private Bank, Amanda Laskey, Life Sciences Senior Analyst, RSM US, and Kee Colon, MBA, Managing Director, Cantor Fitzgerald. The conference, held on May 13, 2025,

      4/14/25 1:53:50 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Molson Coors Nominates Chris Cocks as an Independent Director to Join Its Board of Directors

      The Molson Coors Beverage Company ("Molson Coors" or "the company") (NYSE:TAP, TAP.A)) Board of Directors today announced that Christian "Chris" Cocks has been nominated as an independent Class B director for election at the company's Annual Meeting of Stockholders on May 14, 2025. Cocks is a seasoned consumer goods executive who serves as Chief Executive Officer of Hasbro, Inc (NASDAQ:HAS), a leading games, IP and toy company. "With his background evolving a historic business in the consumer goods industry and a track record of driving commercial and operational success, we believe Chris will bring valuable experience and a great voice to our Board. We are very happy to nominate Chris for

      4/2/25 9:00:00 AM ET
      $HAS
      $MSFT
      $TAP
      Recreational Games/Products/Toys
      Consumer Discretionary
      Computer Software: Prepackaged Software
      Technology

    $MSFT
    $TVGN
    SEC Filings

    See more
    • SEC Form SD filed by Microsoft Corporation

      SD - MICROSOFT CORP (0000789019) (Filer)

      5/30/25 2:19:21 PM ET
      $MSFT
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 424B3 filed by Tevogen Bio Holdings Inc.

      424B3 - Tevogen Bio Holdings Inc. (0001860871) (Filer)

      5/14/25 5:27:46 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Tevogen Bio Holdings Inc.

      10-Q - Tevogen Bio Holdings Inc. (0001860871) (Filer)

      5/14/25 5:27:11 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MSFT
    $TVGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships

      WARREN, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today provided stockholders with a detailed overview of its artificial intelligence initiative, Tevogen.AI™. Tevogen.AI™ aims to integrate advanced machine learning and predictive modeling into Tevogen Bio's proprietary ExacTcell™ technology to significantly enhance its target identification and pre-clinical processes, thereby strengthening the Company's pipeline of innovative immunotherapies, accelerating clinical timelines, and substantially reducing development costs. Tevogen.AI currently has two proprietary technologies, each with patents pending, and an internal valuation

      5/30/25 11:01:18 AM ET
      $MSFT
      $TVGN
      Computer Software: Prepackaged Software
      Technology
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow

      WARREN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced a planned expansion of TVGN 489's target population to include patients 65 and older. As previously reported in October 2024, the top-line revenue forecast for the specialty care pipeline was projected at nearly $1 billion in its launch year, with a cumulative five-year estimate ranging between $18 billion and $22 billion. This anticipated expansion aims to broaden the market potential of Tevogen's specialty pharmaceuticals. An updated forecast and the risk adjusted net present value (rNPV) will be provided to reflect the inclusion of the 65+ patient population.

      5/23/25 3:49:51 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting

      WARREN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced that it will provide several updates to stockholders in advance of the Company's upcoming Annual Meeting of Stockholders scheduled for June 23, 2025. These updates will provide content regarding the Company's innovative business model and strategic growth initiatives, which management believes position the Company strongly for future value realization. Ahead of the annual meeting, Tevogen intends to provide information on: Portfolio Assets: The Company will provide an update on its robust portfolio assets of Tevogen Bio Oncology, Tevogen Bio Specialty Care and

      5/22/25 1:21:42 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MSFT
    $TVGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Strategy Hogan Kathleen T sold $9,756,152 worth of shares (21,500 units at $453.77), decreasing direct ownership by 14% to 134,888 units (SEC Form 4)

      4 - MICROSOFT CORP (0000789019) (Issuer)

      5/22/25 6:06:59 PM ET
      $MSFT
      Computer Software: Prepackaged Software
      Technology
    • EVP, Chief Commercial Officer Althoff Judson sold $7,330,817 worth of shares (16,000 units at $458.18), decreasing direct ownership by 14% to 98,010 units (SEC Form 4)

      4 - MICROSOFT CORP (0000789019) (Issuer)

      5/20/25 6:01:30 PM ET
      $MSFT
      Computer Software: Prepackaged Software
      Technology
    • EVP, Chief Human Resources Off Coleman Amy covered exercise/tax liability with 78 shares and sold $5,985,886 worth of shares (13,243 units at $452.01), decreasing direct ownership by 24% to 43,100 units (SEC Form 4)

      4 - MICROSOFT CORP (0000789019) (Issuer)

      5/16/25 6:07:33 PM ET
      $MSFT
      Computer Software: Prepackaged Software
      Technology

    $MSFT
    $TVGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Tevogen Bio Holdings Inc.

      SC 13G/A - Tevogen Bio Holdings Inc. (0001860871) (Subject)

      11/14/24 5:29:01 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tevogen Bio Holdings Inc.

      SC 13G/A - Tevogen Bio Holdings Inc. (0001860871) (Subject)

      11/12/24 4:28:55 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Tevogen Bio Holdings Inc.

      SC 13G - Tevogen Bio Holdings Inc. (0001860871) (Subject)

      3/4/24 4:24:14 PM ET
      $TVGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care